🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Recruitingn/aAges 18 Years - anyAllPeking Union Medical College
NCT07109765 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * age ≥18 years * diagnosis of moderate-to-severe HS with Hurley stage II or III * Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules * inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors Exclusion Criteria: * active infections (e.g., viral hepatitis, active tuberculosis) * use of other biologics or systemic immunosuppressants within the past three months * severe organ dysfunction (e.g., hepatic or renal failure) * any other conditions that might affect study results
💊

What it tests

  • Secukinumab
📍

Where

1 site
No. 1 Shuai Fu Yuan, Dongcheng District, Beijing
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy